TY - JOUR
T1 - The progression of salt-wasting and the body weight change during the first 2 weeks of life in classical 21-hydroxylase deficiency patients
AU - Gau, Maki
AU - Konishi, Kaoru
AU - Takasawa, Kei
AU - Nakagawa, Ryuichi
AU - Tsuji-Hosokawa, Atsumi
AU - Hashimoto, Atsuko
AU - Sutani, Akito
AU - Tajima, Toshihiro
AU - Hasegawa, Tomonobu
AU - Morio, Tomohiro
AU - Kashimada, Kenichi
N1 - Funding Information:
The present study was partly supported by a grant from the Ministry of Health, Labour and Welfare of Japan (grant Nanbyo‐Ippan046 to TT, TH and KK for research on intractable diseases) [# 201811056A]. We express our deep gratitude to the medical staff who provided the clinical information in the follow‐up survey.
Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2021/2
Y1 - 2021/2
N2 - Background: One of the major purposes of newborn screening for 21-hydroxylase deficiency (21OHD) is preventing life-threatening adrenal crisis. However, the details of adrenal crisis in newborns are not precisely documented. Aim: We aimed to clarify the clinical details of salt-wasting in newborn 21OHD patients. Methods: Based on the follow-up survey of the screening in Tokyo from 1989 to 2017, we retrospectively analysed the conditions of classical 21OHD neonates before the initiation of therapy. Results: One hundred classical 21OHD patients (55 male, 45 female) were analysed. The age at the first hospital visit was 0–20 days with sex difference (male: 9.0 ± 3.5 days; female: 6.2 ± 3.9 days). Thirty-seven (37.4%) patients exhibited severe salt-wasting (SSW), that is, Na < 130 mEq/L, K > 7 mEq/L or Na/K ratio < 20; except for one case, SSW developed in or after the second week of life. The serum concentrations of Na, K and Na/K were linearly correlated with age in days (R2 =.38,.25, and.34 respectively), suggesting that the risk of SSW increases linearly without a threshold. The age at which the regression lines reached Na < 130 mEq/L, K > 7 mEq/L and Na/K < 20 was approximately coincided, 11.1, 12.3 and 11.2 days, respectively. All SSW patients exhibited decreased body weight from birth in their second week of life. Conclusion: Our data revealed that the risk of developing SSW increases during the second week of life without a threshold, and for preventing SSW, early intervention, ideally during first week of life, is desirable. An increased body weight in the second week of life indicates the absence of SSW.
AB - Background: One of the major purposes of newborn screening for 21-hydroxylase deficiency (21OHD) is preventing life-threatening adrenal crisis. However, the details of adrenal crisis in newborns are not precisely documented. Aim: We aimed to clarify the clinical details of salt-wasting in newborn 21OHD patients. Methods: Based on the follow-up survey of the screening in Tokyo from 1989 to 2017, we retrospectively analysed the conditions of classical 21OHD neonates before the initiation of therapy. Results: One hundred classical 21OHD patients (55 male, 45 female) were analysed. The age at the first hospital visit was 0–20 days with sex difference (male: 9.0 ± 3.5 days; female: 6.2 ± 3.9 days). Thirty-seven (37.4%) patients exhibited severe salt-wasting (SSW), that is, Na < 130 mEq/L, K > 7 mEq/L or Na/K ratio < 20; except for one case, SSW developed in or after the second week of life. The serum concentrations of Na, K and Na/K were linearly correlated with age in days (R2 =.38,.25, and.34 respectively), suggesting that the risk of SSW increases linearly without a threshold. The age at which the regression lines reached Na < 130 mEq/L, K > 7 mEq/L and Na/K < 20 was approximately coincided, 11.1, 12.3 and 11.2 days, respectively. All SSW patients exhibited decreased body weight from birth in their second week of life. Conclusion: Our data revealed that the risk of developing SSW increases during the second week of life without a threshold, and for preventing SSW, early intervention, ideally during first week of life, is desirable. An increased body weight in the second week of life indicates the absence of SSW.
KW - congenital adrenal hyperplasia
KW - hyperkalaemia
KW - hyponatremia
KW - newborn screening
KW - salt-wasting crisis
UR - http://www.scopus.com/inward/record.url?scp=85092740209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092740209&partnerID=8YFLogxK
U2 - 10.1111/cen.14347
DO - 10.1111/cen.14347
M3 - Article
C2 - 33001476
AN - SCOPUS:85092740209
SN - 0300-0664
VL - 94
SP - 229
EP - 236
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 2
ER -